Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) of CRA-024781 IV given by 2-hour intravenous
infusions in patients with refractory solid or hematologic malignancies. To evaluate safety
and tolerability, pharmacokinetics and pharmacodynamics, and to evaluate bioavailability of
CRA-024781 IV when administered in a single oral dose.